BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32369413)

  • 21. Role of computed tomography on large B-cell non-Hodgkin's lymphoma follow-up and the risk of radiation-induced neoplasm: A retrospective cohort study.
    Graña L; Calzado A; Hernández P; Rodríguez R
    Eur J Radiol; 2016 Mar; 85(3):673-9. PubMed ID: 26860683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
    Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma.
    Meany HJ; Gidvani VK; Minniti CP
    Pediatr Blood Cancer; 2007 Apr; 48(4):399-402. PubMed ID: 16514616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
    Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
    Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.
    Liedtke M; Hamlin PA; Moskowitz CH; Zelenetz AD
    Ann Oncol; 2006 Jun; 17(6):909-13. PubMed ID: 16672295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
    Adams HJA; Nievelstein RAJ; Kwee TC
    Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
    Pinczés L; Miltényi Z; Illés Á
    J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
    Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma.
    Tang T; Chen Z; Praditsuktavorn P; Khoo LP; Ruan J; Lim ST; Tan D; Phipps C; Lee YS; Goh YT; Hwang W; Tao M; Quek R; Farid M; Furman RR; Leonard JP; Martin P
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):117-21. PubMed ID: 26796979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
    Weihrauch MR; Re D; Scheidhauer K; Ansén S; Dietlein M; Bischoff S; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
    Blood; 2001 Nov; 98(10):2930-4. PubMed ID: 11698273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of prognostic factors in children with B-cell non-Hodgkin lymphoma (B-NHL)].
    Zajac-Spychała O; Derwich K; Mańkowska M; Konatkowska B; Mańkowski P; Wachowiak J
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1087-91. PubMed ID: 19531831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
    Maisey NR; Hill ME; Webb A; Cunningham D; Flux GD; Padhani A; Ott RJ; Norman A; Bishop L
    Eur J Cancer; 2000 Jan; 36(2):200-6. PubMed ID: 10741278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal disease surveillance strategies in non-Hodgkin lymphoma.
    Cohen JB; Flowers CR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):481-7. PubMed ID: 25696898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
    Leuk Lymphoma; 2018 Apr; 59(4):888-895. PubMed ID: 28797213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.